Amarin investors know by now that the big news for the company will be whether its drug Vascepa gets new chemical entity, or NCE, status from the FDA, and so far, the wait has been long for an answer. In the meantime, the company is taking other measures to protect its drug from generic competition. Vascepa was just granted its ninth U.S. patent, and Amarin plans to apply for a 10th. In this video, Motley Fool analysts Max Macaluso and David Williamson discuss another factor that can give the company competitive leverage: increasing the number of suppliers it gets Vascepa's active ingredient from.
The biotech space can make or break investors overnight, and while Amarin certainly won't go under if Vascepa doesn't get NCE status, the success of this new triglyceride-lowering drug is key to the company's future success or failure. The company has huge potential, but don't invest a dollar before reading everything you need to know about Amarin. You can start now with Max's premium research report. Click here now to keep reading.
The article Is This the Key for Amarin? originally appeared on Fool.com.
David Williamson owns shares of Amarin. Max Macaluso, Ph.D., has no positions in the stocks mentioned above. The Motley Fool owns shares of GlaxoSmithKline. Motley Fool newsletter services recommend GlaxoSmithKline. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.